Nventa Announces Final Data From HspE7 Phase 1 Cervical Dysplasia Trial
Nventa Announces Final Data From HspE7 Phase 1 Cervical Dysplasia Trial
Nventa Biopharmaceuticals Corporation (TSX: NVN) announced that it has completed analysis of immunological data from all four cohorts of its Phase 1 clinical trial for HspE7, its lead product candidate. HspE7 is a therapeutic treatment for patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer. The primary cause of CIN is infection with certain human papillomavirus (HPV) types, of which HPV16 is the most common.
What next?
Posting Komentar